Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
MORRISTOWN, N.J., Feb. 18, 2016 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference, as follows.
| Date: | Wednesday, February 24, 2016 |
| Time: | 1:35 PM EST |
| Location: | New York, NY - The New York Palace Hotel |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Matthew P. Duffy, 212.915.0685 LifeSci Advisors, LLC [email protected]
